Clinical trial
A Phase 2 Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab for Previously Untreated Subjects With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)
NCT05835011 is registered in ClinicalTrials.gov with Astex Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab for Previously Untreated Subjects With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- June 27, 2023
- Completion date
- August 21, 2023
- Enrollment
- 2 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.